Today: 19 April 2026
Vodafone share price slips as Centrica partnership lands — and buyback rolls on
27 January 2026
1 min read

Vodafone share price slips as Centrica partnership lands — and buyback rolls on

LONDON, Jan 27, 2026, 08:56 GMT — Regular session

  • Vodafone shares slipped roughly 0.3% in early trading, pulling back after hitting a new 52-week peak on Monday
  • Vodafone Business has inked a four-year deal with Centrica to provide workplace services and connectivity.
  • Vodafone announces additional share repurchases under its ongoing buyback programme

Shares of Vodafone Group Public Limited Company (VOD.L) slipped 0.3% to 104.2 pence by 0841 GMT, pulling back from Monday’s 52-week peak at 105.6 pence. Early trades saw the stock fluctuate between 104.0 and 104.5 pence.

Investors are probing whether Vodafone can translate a string of operational updates into more consistent cash flow and fewer surprises. With core mobile markets maturing and driven by pricing, deals that boost business services revenue carry greater weight.

There’s a more straightforward reason this week is crucial: Vodafone’s shares hover close to a peak. When a stock is priced for growth, traders zero in on the specifics — the pace of new contract rollouts, their delivery costs, and the impact on margins.

Vodafone announced a four-year strategic deal with Centrica (CNA.L), the parent company of British Gas and Hive, through Vodafone Business, VOIS (Vodafone Intelligent Solutions), and IT services provider CGI. The contract covers fixed and mobile services plus IT “end-user compute” support across 80 UK locations and 30,000 devices. Vodafone also plans to deploy generative AI (“GenAI”) and machine learning to automate parts of Centrica’s operations. Nick Gliddon, a business director at VodafoneThree, described the partnership as “a catalyst for real change.” Financial terms were not disclosed. Vodafone

Vodafone revealed it repurchased 2,570,142 ordinary shares on Jan. 26 at a volume-weighted average price of 104.82 pence each. The firm plans to keep these shares in treasury.

UK enterprise connectivity and IT outsourcing is fiercely competitive. BT’s EE and Virgin Media O2 hold strong positions, but securing contracts often leads to lengthy handovers, renegotiations, and the usual scope creep.

Vodafone faces the risk that execution will drag on beyond the initial projections. Major workplace and IT overhauls often run behind schedule, and automation efforts tend to require significant upfront investment before delivering returns—particularly with customers demanding cheaper bills.

Vodafone’s next major date is Feb. 5, when it will release its third-quarter trading update. That day also marks the scheduled interim dividend payment, according to the company’s financial calendar.

Stock Market Today

  • How Defensive Stocks Could Boost Your 401(k) This Summer
    April 18, 2026, 10:58 PM EDT. Seasonal stock market trends suggest selling in May, but experts caution against it in 2026. Instead, financial analysts Mark Hulbert and Sam Stovall recommend rotating investments into defensive stocks during the summer months. These stocks, found in sectors like healthcare and consumer staples, are less sensitive to economic swings and provide stable returns. Hulbert advises using ETFs such as Consumer Staples Select Sector SPDR (XLP) and Health Care Select Sector SPDR (XLV) for this strategy. These ETFs offer low fees and exposure to essential goods and services companies, offering potential portfolio stability during typical market volatility in May to October. This approach could make a meaningful difference to your 401(k) performance by balancing growth and risk through seasonal shifts.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Lloyds share price today: LLOY.L ticks higher as sanctions fine fades and results loom
Previous Story

Lloyds share price today: LLOY.L ticks higher as sanctions fine fades and results loom

BT Group share price edges higher after Monday slide as market eyes Feb 5 update
Next Story

BT Group share price edges higher after Monday slide as market eyes Feb 5 update

Go toTop